Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002418 · ClinicalTrials.gov registry record · Phase 2
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00002418 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 25 participants.
The verdict
NCT00002418, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to give a new anti-HIV drug combination to HIV-infected patients who have never taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) and who have failed to respond to protease inhibitors (PIs). The drug combination will contain didanosine (ddI) plus stavudine (d4T) plus nevirapine (NVP) plus MKC-442. Hydroxyurea (HU) may be added.
Interventions
- DRUG Hydroxyurea
- DRUG Stavudine
- DRUG Didanosine
- DRUG Nevirapine
- DRUG Emivirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002418
The ClinicalTrials.gov registry entry for NCT00002418 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Hydroxyurea is the first listed.
NCT00002418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002418 about?
NCT00002418 is a clinical study titled "The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors". The purpose of this study is to see if it is safe and effective to give a new anti-HIV drug combination to HIV-infected patients who have never taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) and who have failed to respond to protease inhibitors (PIs). The drug combination will contain...
What is the current status of trial NCT00002418?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants.
What interventions are being tested in trial NCT00002418?
The interventions under investigation include: Hydroxyurea (DRUG), Stavudine (DRUG), Didanosine (DRUG), Nevirapine (DRUG), Emivirine (DRUG).
Who is sponsoring clinical trial NCT00002418?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.